Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015

Affiliations

¹ Section of Pathological Anatomy, School of Medicine, University of Udine, Udine, Italy.
² Department of Surgery, Cordoba University Medical School, Cordoba, Spain.
³ Department of Pathology and Laboratory Medicine, Brown University Medical School, Lifespan Academic Medical Center, Providence, RI, USA.
⁴ Molecular Medicine and Cell Therapy Foundation, Polytechnic University of the Marche Region, Ancona, Italy. Electronic address: r.montironi@staff.univpm.it.

Comment

Alessia Cimadamore et al. Eur Urol. 2023 Mar.

. 2023 Mar;83(3):e84-e86.

doi: 10.1016/j.eururo.2022.11.024. Epub 2022 Dec 12.

¹ Section of Pathological Anatomy, School of Medicine, University of Udine, Udine, Italy.
² Department of Surgery, Cordoba University Medical School, Cordoba, Spain.
³ Department of Pathology and Laboratory Medicine, Brown University Medical School, Lifespan Academic Medical Center, Providence, RI, USA.
⁴ Molecular Medicine and Cell Therapy Foundation, Polytechnic University of the Marche Region, Ancona, Italy. Electronic address: r.montironi@staff.univpm.it.

No abstract available

Comment on

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.
Netto GJ, Amin MB, Compérat EM, Gill AJ, Hartmann A, Moch H, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Berney DM. Netto GJ, et al. Eur Urol. 2023 Apr;83(4):301-303. doi: 10.1016/j.eururo.2022.09.015. Epub 2022 Oct 4. Eur Urol. 2023. PMID: 36202687